JP2007502327A5 - - Google Patents

Download PDF

Info

Publication number
JP2007502327A5
JP2007502327A5 JP2006533113A JP2006533113A JP2007502327A5 JP 2007502327 A5 JP2007502327 A5 JP 2007502327A5 JP 2006533113 A JP2006533113 A JP 2006533113A JP 2006533113 A JP2006533113 A JP 2006533113A JP 2007502327 A5 JP2007502327 A5 JP 2007502327A5
Authority
JP
Japan
Prior art keywords
formulation
antagonist
formulation according
tnf
highly specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006533113A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007502327A (ja
Filing date
Publication date
Priority claimed from US10/456,948 external-priority patent/US7344716B2/en
Priority claimed from US10/610,355 external-priority patent/US7429378B2/en
Priority claimed from US10/631,487 external-priority patent/US20040229878A1/en
Priority claimed from US10/640,412 external-priority patent/US7553827B2/en
Application filed filed Critical
Priority claimed from PCT/US2004/015285 external-priority patent/WO2005000283A2/en
Publication of JP2007502327A publication Critical patent/JP2007502327A/ja
Publication of JP2007502327A5 publication Critical patent/JP2007502327A5/ja
Pending legal-status Critical Current

Links

JP2006533113A 2003-05-13 2004-05-13 椎間板変性症の治療法 Pending JP2007502327A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US47009803P 2003-05-13 2003-05-13
US10/456,948 US7344716B2 (en) 2003-05-13 2003-06-06 Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US10/610,355 US7429378B2 (en) 2003-05-13 2003-06-30 Transdiscal administration of high affinity anti-MMP inhibitors
US10/631,487 US20040229878A1 (en) 2003-05-13 2003-07-31 Transdiscal administration of specific inhibitors of P38 kinase
US10/640,412 US7553827B2 (en) 2003-08-13 2003-08-13 Transdiscal administration of cycline compounds
PCT/US2004/015285 WO2005000283A2 (en) 2003-05-13 2004-05-13 A method of treating degenerative disc disease

Publications (2)

Publication Number Publication Date
JP2007502327A JP2007502327A (ja) 2007-02-08
JP2007502327A5 true JP2007502327A5 (https=) 2007-06-28

Family

ID=33556747

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006533113A Pending JP2007502327A (ja) 2003-05-13 2004-05-13 椎間板変性症の治療法

Country Status (8)

Country Link
EP (2) EP1631266B1 (https=)
JP (1) JP2007502327A (https=)
KR (1) KR20060014048A (https=)
AU (1) AU2004251042A1 (https=)
BR (1) BRPI0410331A (https=)
CA (1) CA2525928A1 (https=)
MX (1) MXPA05012275A (https=)
WO (1) WO2005000283A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040054414A1 (en) 2002-09-18 2004-03-18 Trieu Hai H. Collagen-based materials and methods for augmenting intervertebral discs
US7744651B2 (en) 2002-09-18 2010-06-29 Warsaw Orthopedic, Inc Compositions and methods for treating intervertebral discs with collagen-based materials
CN100394989C (zh) 2002-11-15 2008-06-18 华沙整形外科股份有限公司 包含微粒状基于胶原材料的组合物的制药应用和包含所述组合物的滑膜关节
US7344716B2 (en) 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US8273347B2 (en) 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7553827B2 (en) 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US7429378B2 (en) 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US8361467B2 (en) 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US20050100538A1 (en) * 2003-07-31 2005-05-12 Attawia Mohamed Intradiscal injection of anti-oxidants
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
EP1931328A4 (en) * 2005-08-16 2011-07-13 Discogen Llc METHOD FOR TREATING A GREENER SUBJECT WITH DEGENERATIVE DISCOPATHY USING AN INHIBITOR OF NITRIC OXIDE SYNTHASE
CA3008270A1 (en) * 2005-09-21 2007-03-29 The Regents Of The University Of California Systems, compositions, and methods for local imaging and treatment of pain
WO2007098099A2 (en) * 2006-02-16 2007-08-30 Discogen, Llc Method of treating a subject suffering from degenerative disc disease using a matrix metalloprotease inhibitor
US8118779B2 (en) 2006-06-30 2012-02-21 Warsaw Orthopedic, Inc. Collagen delivery device
US8399619B2 (en) 2006-06-30 2013-03-19 Warsaw Orthopedic, Inc. Injectable collagen material
US7928111B2 (en) * 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US8986696B2 (en) 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
ES2915065T3 (es) 2008-07-31 2022-06-20 Firmenich Incorporated Procedimientos para hacer potenciadores del sabor dulce
US20190111178A1 (en) * 2016-04-04 2019-04-18 Gu Ventures Ab Methods and compositions for the treatment of intervertebral disc herniation
WO2019060869A1 (en) * 2017-09-25 2019-03-28 Discitisdx, Inc. METHODS FOR TREATING DEGENERATIVE DISC DISEASE AND CHRONIC LOMBALGIA
US11911504B2 (en) * 2018-02-02 2024-02-27 Galen Therapeutics Llc Apparatus and method for protecting neurons and reducing inflammation and scarring
BR112021002261A2 (pt) 2018-08-07 2021-05-04 Firmenich Incorporated 2,2-dióxidos de 4-amino-1h-benzo[c][1,2,6]tiadiazina 5-substituídos e formulações e usos dos mesmos
CN110613837A (zh) * 2019-10-24 2019-12-27 内蒙古医科大学第二附属医院 TGF-β在制备预防或治疗腰椎间盘突出药物中的应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
JP2647427B2 (ja) 1987-04-24 1997-08-27 帝人株式会社 被検者の病態の判定のための検出方法、モノクロ−ナル抗体および検出キット
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
JP3443119B2 (ja) 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5270300A (en) 1991-09-06 1993-12-14 Robert Francis Shaw Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
NZ331186A (en) 1996-02-02 2000-04-28 Alza Corp Osmotically driven sustained delivery drug delivery capsule
US7115557B2 (en) 1998-09-25 2006-10-03 Sciaticon Ab Use of certain drugs for treating nerve root injury
SE9803710L (sv) * 1998-09-25 2000-03-26 A & Science Invest Ab Användning av vissa substanser för behandling av nervrotsskador
US20010006948A1 (en) * 1998-11-25 2001-07-05 James D. Kang Gene transfer to intervertebral disc cells
US6419944B2 (en) 1999-02-24 2002-07-16 Edward L. Tobinick Cytokine antagonists for the treatment of localized disorders
US6015557A (en) * 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
US6982089B2 (en) 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
US6537549B2 (en) * 1999-02-24 2003-03-25 Edward L. Tobinick Cytokine antagonists for the treatment of localized disorders
US6428576B1 (en) * 1999-04-16 2002-08-06 Endospine, Ltd. System for repairing inter-vertebral discs
US6352557B1 (en) 1999-08-13 2002-03-05 Bret A. Ferree Treating degenerative disc disease through transplantion of extracellular nucleus pulposus matrix and autograft nucleus pulposus cells
US6541477B2 (en) 1999-08-27 2003-04-01 Scios, Inc. Inhibitors of p38-a kinase
US20020032155A1 (en) * 2000-06-30 2002-03-14 Ferree Bret A. Method of treating disc herniation and disc degeneration with concentrated growth and differentiation factors
US20020026244A1 (en) 2000-08-30 2002-02-28 Trieu Hai H. Intervertebral disc nucleus implants and methods
MXPA03005777A (es) 2000-12-22 2005-02-14 Johnson & Johnson Derivados de triazol diaminas sustituidos como inhibidores de cinasa.
SE0102067D0 (sv) 2001-06-11 2001-06-11 A & Science Invest Ab Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation
US20050123593A1 (en) 2001-06-25 2005-06-09 Jonathan Thompson Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints

Similar Documents

Publication Publication Date Title
JP2007502327A5 (https=)
Kay et al. The role of interleukin-1 in the pathogenesis of rheumatoid arthritis
Zou et al. Tumor necrosis factor‐α mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism
Kirkwood et al. Novel host response therapeutic approaches to treat periodontal diseases
Esteban et al. Effect of simultaneous blockade of AT1 and AT2 receptors on the NFκB pathway and renal inflammatory response
Hofbauer et al. The role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases
Bluthé et al. Central mediation of the effects of interleukin-1 on social exploration and body weight in mice
Yamada et al. Candesartan, an angiotensin II receptor antagonist, suppresses pancreatic inflammation and fibrosis in rats
Arend The mode of action of cytokine inhibitors.
WinZen et al. Selective up-regulation of the 75-kDa tumor necrosis factor (TNF) receptor and its mRNA by TNF and IL-1
Tracey et al. Tumor necrosis factor and regulation of metabolism in infection: role of systemic versus tissue levels
JP2007500723A5 (https=)
Ando et al. Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA)
WO2002096461A1 (en) Use of anti-tnf antibodies as drugs in treating septic disorders of anemic patients
CA2182723A1 (en) The use of anti-tnf antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6
JP2009507838A5 (https=)
JP2005525352A5 (https=)
US11773158B2 (en) Method of treatment of a tumor with an IL-8 antibody
AU2004251042A1 (en) A method of treating degenerative disc disease
Roodman Treatment strategies for bone disease
Hanifin Atopic dermatitis: new therapeutic considerations
Ito et al. Dual role of interleukin-17 in pannus growth and osteoclastogenesis in rheumatoid arthritis
SK287522B6 (sk) Použitie inhibítorov produkcie a/alebo účinku IL-18
Lin et al. The renoprotective potential of pentoxifylline in chronic kidney disease
Thannickal et al. Emerging drugs for idiopathic pulmonary fibrosis